logo_ProQR-150x150.png
ProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Business Update
February 26, 2020 07:00 ET | ProQR Therapeutics N.V.
Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal...
ProQR logo1200x1200.png
ProQR to Present at Upcoming Investor Conferences
November 13, 2019 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...
ProQR logo1200x1200.png
ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019
November 06, 2019 07:00 ET | ProQR Therapeutics N.V.
Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1 2020QR-1123...
ProQR logo1200x1200.png
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 18, 2019 08:20 ET | ProQR Therapeutics N.V.
LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of...
ProQR logo1200x1200.png
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
October 15, 2019 16:13 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of...
ProQR logo1200x1200.png
ProQR to Present at Two Investor Conferences in October
September 30, 2019 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...
34945.jpg
ProQR Announces Financial Results for the Second Quarter of 2019
August 07, 2019 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...
34945.jpg
ProQR to Present at the RBC Capital Markets Healthcare Conference
May 15, 2019 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, the Netherlands and CAMBRIDGE, Mass., May 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...
34945.jpg
ProQR to Present at Three Scientific Conferences in April
April 22, 2019 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., April 22, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
34945.jpg
ProQR Announces Annual Meeting of Shareholders
April 18, 2019 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., April 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...